Drugs / LUCAR-G79D
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07331272 | Jan 2026 → Jan 2028 expected | idiopathic inflammatory myopathy, systemic lupus erythematosus | Nanjing Legend Biotech Co. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LUCAR-G79D | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07331272 ↗ |
| Modality | Cell therapy | “a chimeric antigen receptor (CAR) -T cell therapy” NCT07331272 ↗ |